A Study of LY2605541 and Glargine and Exercise in Participants With Type 1 Diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01784211|
Recruitment Status : Completed
First Posted : February 5, 2013
Results First Posted : March 15, 2019
Last Update Posted : March 15, 2019
|Study Design||Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Basic Science|
Diabetes Mellitus, Type 1
Drug: Insulin Glargine
Part A is 2- arm parallel open label.
Part B is a crossover study with 2 treatment arms (LY2605541 & Glargine), each treatment arm consists of 2 sequences.
Sequence 1: participants received treatment on days 16,17,18,19 & 20 with exercise on day 17.
Sequence 2: participants received treatment on days 16,17,18,19, & 20 with exercise on day 20.